• Taltirelin Acetate: Applied Protocols and Troubleshooting in

  2026-05-20

  Taltirelin acetate empowers neurodegeneration and itch research with selective, long-acting modulation of the TRH pathway. This article details optimized workflows, practical troubleshooting, and how recent regulatory advances in bioequivalence testing can streamline your experimental design.

• Cisplatin in Translational Oncology: Mechanisms and Strategi

  2026-05-19

  Explore how the mechanistic nuances of Cisplatin (CDDP)—from DNA crosslinking to apoptosis induction—shape both experimental oncology and clinical innovation. This thought-leadership article integrates new findings on DNA damage repair modulation, competitive benchmarking, and practical guidance for translational researchers, with actionable protocol parameters and a strategic outlook.

• Caspase-3 Colorimetric Assay Kit: Workflow Parameters & QC G

  2026-05-19

  The Caspase-3 Colorimetric Assay Kit enables reproducible and sensitive quantification of caspase-3 activity in apoptosis studies, especially where a cysteine-dependent aspartate-directed protease is a key biomarker. This kit is most suitable for applications in neurodegenerative disease and apoptosis assay workflows, but should not be used for non-DEVD-dependent caspase detection or in cases where substrate specificity is a concern.

• Cyclophosphamide Workflows: Applied Protocols for Cancer Res

  2026-05-18

  Cyclophosphamide, a leading alkylating chemotherapeutic agent, is pivotal in driving apoptosis induction and immune modulation across cancer and transplantation research. This detailed guide translates recent experimental advances and troubleshooting strategies into actionable protocols, maximizing reproducibility and translational relevance for oncology workflows.

• Cytarabine (AraC): Mechanistic Strategy for Translational Im

  2026-05-18

  This thought-leadership article unites the mechanistic insights of Cytarabine (AraC) as a DNA synthesis inhibitor and apoptosis inducer with actionable guidance for translational researchers. It weaves together the latest findings on regulated cell death, resistance mechanisms, and viral evasion strategies, highlighting the relevance of Cytarabine in leukemia and beyond. APExBIO’s Cytarabine is positioned as the gold-standard research tool, with evidence-backed protocol recommendations and critical appraisal of cross-domain opportunities.

• Anlotinib in Intra-Abdominal Desmoplastic Small Round Cell T

  2026-05-17

  This article examines the first documented use of anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, in the treatment of intra-abdominal desmoplastic small round cell tumor (IADSRCT). The case report demonstrates clinically meaningful tumor regression and manageable toxicity, highlighting anlotinib’s translational potential for rare, treatment-resistant sarcomas.

• Gastroretentive Alfuzosin HCl Sponges: MRI-Backed Design and

  2026-05-16

  This study presents a novel low-density, gastroretentive sponge system for Alfuzosin HCl, engineered to enhance oral bioavailability by prolonging gastric residence and sustaining drug release. MRI validation in healthy volunteers confirms the system's retention and potential utility for benign prostatic hyperplasia research.

• Sex-Biased Gene Expression in Neural Differentiation of hESC

  2026-05-15

  This study reveals that genetic sex differences, independent of hormonal factors, significantly impact gene expression during neural differentiation of human embryonic stem cells (hESCs). These findings highlight key sex-biased genes and pathways with implications for understanding sex-specific neurodevelopment and its relevance to neurological disease risk.

• Staurosporine: Broad-Spectrum Kinase Inhibitor in Cancer Res

  2026-05-15

  Staurosporine is a gold-standard broad-spectrum serine/threonine protein kinase inhibitor, pivotal for dissecting apoptosis and kinase signaling in cancer models. This guide translates the latest high-throughput microscopy workflows and troubleshooting strategies, empowering researchers to optimize Staurosporine-based assays with confidence.

• Hoechst 33342: Applied Workflows for Advanced Nuclear Analys

  2026-05-14

  Hoechst 33342 stands out as a bis-benzimidazole fluorescent dye enabling crisp, selective nuclear visualization in live and fixed cells. Explore how this dye powers robust cell cycle, apoptosis, and chromatin assays—with advanced troubleshooting and protocol optimization for reproducible, high-contrast results in demanding research contexts.

• Clasto-Lactacystin β-lactone: Advancing Proteasome Inhibitor

  2026-05-14

  Clasto-Lactacystin β-lactone enables precise, irreversible proteasome inhibition, empowering researchers to dissect protein degradation pathways in complex cellular models. This article demystifies its stepwise application, troubleshooting, and translational value in ubiquitin-proteasome pathway research, with actionable insight drawn from cutting-edge viral immunology.

• Novel Fluorinated CXCR4 Inhibitor A1 Outperforms AMD3100 in

  2026-05-13

  Khorramdelazad et al. introduce A1, a fluorinated small-molecule CXCR4 inhibitor, demonstrating superior efficacy to AMD3100 in colorectal cancer (CRC) models. Their study integrates advanced simulation, cell-based assays, and in vivo validation, revealing A1's enhanced binding, tumor suppression, and immunomodulatory effects.

• Plasma GPNMB Model Predicts Immunotherapy Response in ESCC

  2026-05-13

  This study introduces a multimodal model integrating circulating GPNMB, CAF-Epi niche features, and clinicopathological factors to predict immunotherapy response in esophageal squamous cell carcinoma (ESCC). The research uncovers mechanistic links between tumor-derived sGPNMB and CD8+ T cell exhaustion, providing a clinically scalable framework for precision immunotherapy selection.

• FXR-KLF11 Axis Suppresses JAK2/STAT3 in CI-AKI: CDCA’s Mecha

  2026-05-12

  This study defines a mechanistic pathway in which Chenodeoxycholic Acid (CDCA) activates FXR to transcriptionally upregulate KLF11, thereby suppressing the JAK2/STAT3 pathway in contrast-induced acute kidney injury (CI-AKI) models. The findings clarify the FXR-KLF11 axis as a potential prophylactic target in renal injury and inform translational approaches for nuclear receptor signaling research.

• Elobixibat Hydrate: Precision IBAT Inhibition in Metabolic D

  2026-05-12

  Explore Elobixibat hydrate as a highly selective ileal bile acid transporter inhibitor for advanced metabolic and gastrointestinal research. This article provides an in-depth analysis of its mechanism, assay protocols, and translational impact, uniquely connecting clinical pharmacology with experimental design.

458 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page